Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

March 2022 | 65 pages | ID: IF6742877BB0EN
Global Markets Direct

Abstracts

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 1 and 6 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.

The latest report Iduronate 2 Sulfatase - Drugs In Development, 2022, outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
• The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
• The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
AngioChem Inc
AVROBIO Inc
Bioasis Technologies Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Homology Medicines Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
History of Events
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
History of Events
idursulfase - Drug Profile
Product Description
Mechanism Of Action
History of Events
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pabinafusp alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
History of Events
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SIG-018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Dormant Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Discontinued Products
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: JCR announces first patient dosed in phase 3 global clinical trial of JR-141 for treatment of MPS II (Hunter Syndrome)
Feb 10, 2022: Homology medicines announces presentations on HMI-203 investigational gene therapy for Hunter syndrome and broad applicability of AAVHSC platform for lysosomal storage disorders at the 18th Annual WORLDSymposium meeting
Feb 10, 2022: Denali Therapeutics announces continued progress in DNL310 program for MPS II (Hunter Syndrome) supporting planned initiation of Phase 2/3 clinical trial
Feb 09, 2022: REGENXBIO presents additional positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium 2022
Feb 03, 2022: JCR Pharmaceuticals receives the WORLDSymposium new treatment award for IZCARGO (Pabinafusp Alfa)
Feb 03, 2022: JCR pharmaceuticals to present posters on JR-141 at the 18th annual WORLDSymposium 2022
Feb 01, 2022: Denali therapeutics announces presentations on DNL310 (ETV:IDS) development program in MPS II (hunter syndrome) at the upcoming WORLDsymposium
Nov 29, 2021: Immusoft receives $4M in funding from the California Institute for Regenerative Medicine (CIRM)
Nov 08, 2021: AVROBIO to present preclinical data on AVRRD-05 at the 14th ICIEM Conference
Nov 03, 2021: AVROBIO receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Nov 02, 2021: GC Green Cross designated as a European orphan drug for the treatment of severe Hunter syndrome
Oct 20, 2021: Homology Medicines announces presentation of data supporting clinical programs in MPS II and PKU, including nonclinical and patient-focused research, at American Society of Human Genetics Meeting
Oct 18, 2021: Homology medicines initiates clinical trial for HMI-203, a one-time investigational gene therapy candidate for adults with MPS II (Hunter Syndrome)
Oct 18, 2021: JCR Pharmaceuticals Co : EMA grants PRIME designation for JR-141 for the treatment of Mucopolysaccharidosis type II (Hunter Syndrome)
Oct 15, 2021: JR-141 (Pabinafusp Alfa) for Hunter syndrome notice on the publication of a nonclinical and clinical evidence in International Journal of Molecular Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AngioChem Inc, 2022
Pipeline by AVROBIO Inc, 2022
Pipeline by Bioasis Technologies Inc, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Esteve Pharmaceuticals SA, 2022
Pipeline by GC Pharma, 2022
Pipeline by Homology Medicines Inc, 2022
Pipeline by Immusoft Corp, 2022
Pipeline by JCR Pharmaceuticals Co Ltd, 2022
Pipeline by RegenxBio Inc, 2022
Pipeline by Sigilon Therapeutics Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022